XRHealth Secures $10M in Funding

Funding to Expand Virtual Reality Healthcare Treatment in the Metaverse

XRHealth, the gateway to the healthcare metaverse,  announced today that they raised $10M in funding to expand virtual healthcare treatment in the Metaverse. The funding was backed by HTC, Bridges Israel impact investment fund, AARP, and crowdfunding on StartEngine.com and existing investors.

“Together, we’re taking the next step in growing the open ecosystem and providing greater access to care while reducing costs. Interoperability is key and working with XRHealth opens a world of possibilities in using technology for good,” said Cher Wang, HTC Co-Founder and Chairwoman.

In a recent McKinsey report, the economic opportunity of virtual healthcare is presented as a possible quarter trillion dollar market. Virtual treatment rooms provide further opportunities for clinicians to expand their business, improve access for patients to receive care, and creates the simplicity and comfort for users to engage in therapeutic treatment from the comfort of their home.

As a pioneer of virtual healthcare treatment, XRHealth is creating a major imprint on the healthcare metaverse presence by expanding their accessibility to patients worldwide, connecting patients with treating clinicians.

“XRHealth is putting Virtual Clinics into users’ pockets at a critical time in the changing landscape of the medical delivery and the technology industry,” says Eran Orr, Chief Executive Officer of XRHealth. “We are leveraging these changes to create a new form of healthcare that is accessible at any time of day, from any location in the virtual environment of the metaverse, where treatment can be personalized and adjusted based on real-time analytics.”

“Widely covered by insurance providers XRHealth’s virtual clinics inclusively improves access to quality care and enhances the efficacy of healthcare treatment,” says Gal Hayut, Managing Partner at Bridges Israel and a member on XRHealth’s board. “As an impact-tech investor we see the company’s growth, positive clinical results alongside high patients’ satisfaction as an indication of its tangible impact on patients’ wellbeing.”

XRHealth’s platform is FDA and CE registered and provides an immersive experience for users, transporting them to a virtual world for comprehensive therapeutic care. Patient care is covered by Medicare and is available under most major insurance providers.

SourceXRHealth

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version